COMMON STOCK PURCHASE WARRANT Nexalin technology, inc.Common Stock Purchase Warrant • April 8th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _____1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Nexalin Technology Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of this Warrant, subject to a Holder’s right t
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 24th, 2024 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of [●], 2024, between Nexalin Technology, Inc. (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
NEXALIN TECHNOLOGY, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • April 8th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • New York
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • June 28th, 2024 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • New York
NEXALIN TECHNOLOGY, INC. Up to [●] Shares of Common Stock EQUITY DISTRIBUTION AGREEMENTEquity Distribution Agreement • April 16th, 2024 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • New York
Nexalin Technology, Inc., a Delaware corporation (the “Company”), proposes to issue and sell through Maxim Group LLC (the “Agent”), as exclusive sales agent, shares of common stock, par value $[●] per share (“Common Stock”), of the Company (the “Shares”) having an aggregate offering price of up to $[●] on terms set forth herein. The Shares consist entirely of authorized but unissued shares of Common Stock to be issued and sold by the Company.
NEXALIN TECHNOLOGY, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 16th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • New York
Nexalin Technology, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell an aggregate of 2,315,000 units (the “Units”), with each Unit consisting of (a) one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”), and (b) one warrant to purchase one share of Common Stock (the “Warrants”) (collectively, the “Firm Units”) to the several underwriters (such underwriters, for whom Maxim Group LLC (“Maxim” or the “Representative”) is acting as representative, the “Underwriters” and each an “Underwriter”). The Company has also agreed to grant to the Representative on behalf of the Underwriters an option (the “Option”) to purchase up to an additional 347,250 shares of Common Stock, representing fifteen percent (15%) of the shares of Common Stock sold as part of the Firm Units sold in the offering (the “Option Shares”), and/or 347,250 Warrants, representing fifteen percent (15%) of the Warrants
Form of Lock-Up AgreementLock-Up Agreement • June 24th, 2024 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus
COMMON STOCK PURCHASE WARRANT AGREEMENT Nexalin technology, inc.Common Stock Purchase Warrant Agreement • September 20th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • New York
THIS COMMON STOCK PURCHASE WARRANT AGREEMENT (the “Warrant”) dated as of September 16, 2022 is entered into by and between NEXALIN TECHNOLOGY INC., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”).
EMPLOYMENT AGREEMENTEmployment Agreement • January 4th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • Nevada
EMPLOYMENT AGREEMENT (this “Agreement”) dated as of February 15, 2021 between DAVID OWENS, MD (the “Executive”) and NEXALIN TECHNOLOGY INC. (the “Company”).
EMPLOYMENT AGREEMENTEmployment Agreement • January 4th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • Nevada
EMPLOYMENT AGREEMENT (this “Agreement”) dated as of February 15, 2021 between MARK WHITE (the “Executive”) and NEXALIN TECHNOLOGY INC. (the “Company”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 10th, 2023 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
EMPLOYMENT AGREEMENT (this “Agreement”) dated as of July 1, 2023 (“Effective Date”) between MARK WHITE (the “Executive”) and NEXALIN TECHNOLOGY INC. (the “Company”).
JOINT VENTURE AGREEMENTJoint Venture Agreement • January 4th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • Hong Kong
JOINT VENTURE AGREEMENT, dated as of September 21, 2018 (this “Agreement’), is by and between Nexalin Technology, Inc., a Nevada corporation (“Nexalin”), and [Wider come Limited], a company formed under the laws of [Hong Kong] (‘Wider’’,and together with Nexalin, collectively, the “parties” and each, a “party”).
Apical Quality AgreementQuality Agreement • January 4th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus
US ASIAN CONSULTING GROUP, LLCConsulting Agreement • April 8th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus
This letter confirms our agreement that US Asian has agreed to defer payments of $250,000 otherwise due to it in connection with fees owed to it under Consulting Agreement. We further confirm that the payments have been deferred until December 15, 2022.
JOINT VENTURE AGREEMENTJoint Venture Agreement • August 10th, 2023 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • New York
JOINT VENTURE AGREEMENT (this “Agreement”) dated as of May 31, 2023 (the “Effective Date”), by and between Nexalin Technology, Inc., a Nevada corporation (“Nexalin”), and Wider Come Limited, a company formed under the laws of the People’s Republic of China (“Wider”, and together with Nexalin, collectively, the “parties” and each, a “party”).
SUPPLEMENTARY AGREEMENT NO. 2 FOR JOINT VENTURE AGREEMENTJoint Venture Agreement • April 8th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus
This SUPPLEMENTARY AGREEMENT NO. 2 FOR JOINT VENTURE AGREEMENT is entered into as of the 9th day of March, 2022 by and between NEXALIN TECHNOLOGY, INC. (’‘Nexalin”) and WIDER COM LIMITED (“Wider”). Nexalin and Wider are sometimes individually referred to as a ’‘Party” and collectively as the “Parties”.
EMPLOYMENT AGREEMENTEmployment Agreement • January 31st, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
EMPLOYMENT AGREEMENT (this “Agreement”) dated as of January 11, 2022 between Marilyn Elson (the “Executive”) and NEXALIN TECHNOLOGY INC. (the “Company”).
AMENDMENT NO 1 TO EMPLOYMENT AGREMENT BETWEEN DAVID OWENS MD AND NEXALIN TECHNOLOGY INC.Employment Agreement • April 8th, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus
This Amendment No. 1 to Employment Agreement is made as of March _, 2022 by and between David Owens M.D. (“Executive”) and Nexalin Technology Inc. (the “Company”).
Form of Underwriters’ Warrants AgreementUnderwriters’ Warrants Agreement • January 31st, 2022 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • New York
THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
SERVICES AGREEMENTServices Agreement • August 10th, 2023 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus • Delaware
SERVICES AGREEMENT (this “Agreement”) dated as of July 1, 2023 (the “Effective Date”) between DAVID OWENS, M.D. (the “Consultant”) and NEXALIN TECHNOLOGY, INC. (the “Company”).
Apical Quality AgreementQuality Agreement • November 2nd, 2021 • Nexalin Technology, Inc. • Electromedical & electrotherapeutic apparatus
